Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 8/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31119271 | 0.94 | CYP1A2 (0.40) | CYP1A2CYP3A4HPGDCDK2CDK4 | |
| SCHEMBL31119263 | 0.84 | CYP1A2 (0.40) | CYP1A2CYP3A4HPGDCYP2C19CLK4 | |
| SCHEMBL31119265 | 0.84 | CYP1A2 (0.40) | CYP1A2CYP3A4HPGDCYP2C19CLK4 | |
| SCHEMBL31119323 | 0.84 | CDK4 (0.43) | CYP1A2CYP3A4HPGDCDK2CDK4 | |
| SCHEMBL31119305 | 0.83 | SCD (0.45) | CYP1A2CYP3A4HPGDCYP2C19CLK4 | |
| SCHEMBL31501293 | 0.83 | CLK4 (0.41) | CYP1A2CYP3A4HPGDCYP2C19CLK4 | |
| SCHEMBL31119332 | 0.82 | SCD (0.42) | CYP1A2CYP3A4HPGDCLK4ALDH1A1 | |
| SCHEMBL31119328 | 0.82 | SCD (0.42) | CYP1A2CYP3A4HPGDCLK4ALDH1A1 | |
| SCHEMBL31119280 | 0.82 | ALDH1A1 (0.41) | CYP1A2CYP3A4HPGDCYP2C19CLK4 | |
| SCHEMBL31119249 | 0.81 | POLB (0.45) | CYP1A2CYP3A4HPGDCYP2C19CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4683919-A1 | VANIN-1 INHIBITORS | Athos Therapeutics, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250066353-A1 | VANIN-1 INHIBITORS | ATHOS THERAPEUTICS INC (US) | 2025-02-27 | — | — | US | disclosed |
| WO-2024196841-A1 | VANIN-1 INHIBITORS | ATHOS THERAPEUTICS, INC. (US) | 2024-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066353-A1 | VANIN-1 INHIBITORS | VCAM1, TMBIM6, VNN1 | CYP1A2 2868/4885CYP3A4 2422/4885HPGD 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.